<?xml-stylesheet type="text/xsl" href="https://www.vetsurgeon.org/utility/feedstylesheets/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Genitrix announces HY-50 now authorised for IV use</title><link>/b/veterinary-news/posts/2989</link><description> Genitrix has announced that HY-50 Vet &amp;#174; , a sodium hyaluronate treatment for equine joints, has now been authorised for intravenous (IV) use. 
 Available until now for intra-articular (IA) use only, the company says HY-50 delivers the highest concentration</description><dc:language>en-US</dc:language><generator>Telligent Community 10</generator></channel></rss>